Friday, March 15, is the FINAL day to renew your ASGCT membership for 2024! Renew to maintain your exclusive benefits.
The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Citeline, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
In Q4 2023:
FDA approved two cell-based gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease
Casgevy is the first approved therapy in the U.S. that uses CRISPR
Two RNA therapies were also approved in the U.S.
Read the Full Report
Read all the landscape reports from 2023.
Read all the landscape reports from 2022.
Read all the reports from 2021 here.
May 7-11, 2024 | Baltimore, MD
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico